Latest Regulatory News

VGI Partners Global Investments has completed its on-market share purchases under the Dividend Reinvestment Plan, updating investors with a new Appendix 3A.1 filing.

ASX Limited has updated its dividend notification to include the New Zealand dollar exchange rate, NZD equivalent dividend amount, and the dividend reinvestment plan price for the first half of FY25.

Latitude 66 Limited has responded to an ASX price query concerning unusual trading activity, confirming no undisclosed material information exists and referencing prior announcements about a joint venture sale and recent assay results.

Tasmea Limited has launched a $43 million institutional placement to strengthen its balance sheet for future acquisitions, following a robust FY25 with significant profit growth and margin expansion. The company’s FY26 guidance signals continued momentum driven by organic growth and strategic acquisitions.

Wagners Holding Company Limited has launched a A$30 million institutional placement to reduce debt and accelerate growth in its core Construction Materials and Composite Fibre Technologies businesses following a robust FY25 performance.

Wagners Holding Company Limited has secured $30 million through a strongly supported placement to fund growth in its construction materials and composite fibre technologies divisions.

Kuniko Limited updates its prospectus to extend its entitlement offer, enter a joint venture for the Commonwealth Project, and secure partial underwriting from GBA Capital.

Kuniko Limited has launched a partially underwritten rights issue to fund exploration at its Commonwealth Gold-Silver Project in New South Wales, aiming to capitalise on high-grade multi-metal potential in a Tier-1 jurisdiction.

The Federal Court has dismissed most ASIC claims against Money3 Loans, a Solvar subsidiary, affirming its compliance with responsible lending standards while identifying limited breaches in a handful of consumer loans.

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.

PolarX Limited's trading suspension has been lifted immediately following its announcement of a new capital raising, signaling renewed market activity for the mining explorer.

Coles Group reveals a significant potential financial impact following a Federal Court decision on underpayments to salaried team members, estimating remediation costs between $150 million and $250 million.